WIN 901X

Drug Profile

WIN 901X

Alternative Names: WIN-901; WIN901X

Latest Information Update: 22 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Whanin Pharmaceutical
  • Class Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 22 Feb 2016 Phase-II development is ongoing in South Korea (Whanin Pharm pipeline, February 2016)
  • 30 Nov 2013 Whanin Pharmaceutical Company completes a phase II trial in Asthma in South Korea (NCT01820481)
  • 30 Sep 2012 Phase-II clinical trials in Asthma in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top